Related Experiment Videos
Transurethral enzyme injection--future management of benign prostatic hyperplasia
1Department of Urology, Mayo Clinic Rochester, Minnesota 55905, USA.
Mayo Clinic Proceedings
|September 16, 1998
Summary
Transurethral enzyme injection offers a minimally invasive alternative for treating benign prostatic hyperplasia (BPH). This novel approach shows promise for alleviating urinary obstruction with reduced risks compared to traditional surgery.
Area of Science:
- Urology
- Minimally Invasive Surgery
- Enzyme Therapeutics
Background:
- Benign prostatic hyperplasia (BPH) is a prevalent condition in aging men.
- Transurethral resection of the prostate (TURP) is a common BPH treatment but carries significant risks.
- There is a need for safer, alternative BPH management strategies.
Purpose of the Study:
- To investigate the potential of transurethral enzyme injection for BPH treatment.
- To evaluate enzyme-mediated prostatic tissue ablation as a therapeutic option.
- To explore a less invasive approach for managing urinary outlet obstruction.
Main Methods:
- Enzyme solubilization and ablation of prostatic tissue.
- Transurethral delivery of enzymes into the prostate.
- Pre-clinical evaluation in canine models.
Main Results:
- Enzyme injection effectively solubilized and ablated prostatic tissue.
- The method showed promise in alleviating urinary outlet obstruction in canine studies.
- Potential for minimal invasiveness and reduced toxicity was indicated.
Conclusions:
- Transurethral enzyme injection is a promising, minimally invasive treatment for BPH.
- This technique may offer a safer alternative to TURP with fewer complications.
- Further human trials are warranted to validate its efficacy and safety in patients.